Nielsen Henriette 4

What Happened

• Henriette Nielsen, EVP & Chief Transformation Officer of Keenova Therapeutics plc, was granted 51,794 restricted stock units (RSUs) on February 25, 2026. The filing shows an acquisition-type derivative award (code A) at $0.00 per unit; no cash was exchanged at grant.
• Each RSU will settle into one ordinary share upon vesting, so the award represents a potential future issuance of 51,794 shares if all units vest.

Key Details

• Transaction date and type: 2026-02-25 — Grant of 51,794 RSUs (derivative award, code A) recorded at $0.00.
• Vesting: RSUs vest ratably on each of the first three anniversaries of February 25, 2027 (i.e., vesting begins 2/25/2027 and continues annually for three years). (Footnotes F1–F2)
• Settlement: Each vested RSU converts to one ordinary share upon vesting (F1).
• Shares owned after transaction: Not disclosed in the supplied filing excerpt.
• Filing timeliness: Report filed 2026-02-26 for a 2026-02-25 transaction (appears timely).
• Regulatory note: The Form 4 also serves as notice to the issuer under Part V of the Companies Act 2014 per the filing remarks.

Context

• RSU grants are a common form of executive compensation and are not an immediate purchase or sale; value to the insider depends on future stock price at vesting. This award does not indicate an immediate change in market supply from insider selling.
• As a derivative award (not an option exercise or open-market trade), the disclosure documents future potential share issuance rather than a cash transaction.